Showing results (321-330 of 348) with videos related to

Sort By:
Pageof 35
The American Journal of Gastroenterology|June 24, 2025
Long-Term Efficacy and Safety of Selective PPARδ Agonist Seladelpar in Primary Biliary Cholangitis: ASSURE Interim Study ResultsCynthia Levy, Palak J Trivedi, Kris V Kowdley, et al.
The American Journal of Gastroenterology|August 14, 2024
COBALT: A Confirmatory Trial of Obeticholic Acid in Primary Biliary Cholangitis With Placebo and External ControlsKris V Kowdley, Gideon M Hirschfield, Charles Coombs, et al.
Gut|January 9, 2015
Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international studyPalak J Trivedi, Willem J Lammers, Henk R van Buuren, et al.
Journal of Hepatology|September 28, 2025
Phase II INTEGRIS-PSC trial of bexotegrast, an αvβ6/αvβ1 integrin inhibitor, in primary sclerosing cholangitisGideon M Hirschfield, Kris V Kowdley, Palak J Trivedi, et al.
Hepatology (Baltimore, Md.)|December 20, 2018
Factors Associated With Outcomes of Patients With Primary Sclerosing Cholangitis and Development and Validation of a Risk Scoring SystemElizabeth C Goode, Allan B Clark, George F Mells, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 17, 2025
Development of a Question Prompt List for People Living With Primary Biliary Cholangitis: A Delphi StudyEllen Werner, Maria C B van Hooff, Gemma H X Weijsters, et al.
Gastroenterology|August 12, 2015
Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid TherapyWillem J Lammers, Gideon M Hirschfield, Christophe Corpechot, et al.
Alimentary Pharmacology & Therapeutics|October 18, 2019
Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment responseCarla F Murillo Perez, Gideon M Hirschfield, Christophe Corpechot, et al.
Pageof 35